HRP20201575T1 - Kombinacija dva protuvirusna sredstva namijenjena liječenju hepatitisa c - Google Patents
Kombinacija dva protuvirusna sredstva namijenjena liječenju hepatitisa c Download PDFInfo
- Publication number
- HRP20201575T1 HRP20201575T1 HRP20201575TT HRP20201575T HRP20201575T1 HR P20201575 T1 HRP20201575 T1 HR P20201575T1 HR P20201575T T HRP20201575T T HR P20201575TT HR P20201575 T HRP20201575 T HR P20201575T HR P20201575 T1 HRP20201575 T1 HR P20201575T1
- Authority
- HR
- Croatia
- Prior art keywords
- daas
- patient
- treatment according
- infected
- treatment
- Prior art date
Links
- 239000003443 antiviral agent Substances 0.000 title claims 2
- 229940121357 antivirals Drugs 0.000 title 1
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 6
- 229940125782 compound 2 Drugs 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 229940125904 compound 1 Drugs 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (15)
1. Najmanje dva izravno djelujuća protuvirusna sredstva (DAA) namijenjena upotrebi u postupku liječenja zaraze HCV-om, naznačena time što se navedeni postupak sastoji u primjeni najmanje dva DAA na pacijentu s HCV-om, što se na navedenom pacijentu ne primjenjuje ni interferon niti ribavirin tijekom navedenog liječenja, a navedeno liječenje traje 16 tjedana, te što navedena najmanje dva DAA sadrže:
[image]
,
ili njegova farmaceutski prihvatljivu sol, i
[image]
,
ili njegova farmaceutski prihvatljivu sol.
2. Najmanje dva DAA namijenjena liječenju u skladu s patentnim zahtjevom 1, naznačena time što je navedeni pacijent zaražen HCV genotipom 1.
3. Najmanje dva DAA namijenjena liječenju u skladu s patentnim zahtjevom 1, naznačena time što je navedeni pacijent zaražen HCV genotipom 1a.
4. Najmanje dva DAA namijenjena liječenju u skladu s patentnim zahtjevom 1, naznačena time što je navedeni pacijent zaražen HCV genotipom 2.
5. Najmanje dva DAA namijenjena liječenju u skladu s patentnim zahtjevom 1, naznačena time što je navedeni pacijent zaražen HCV genotipom 3.
6. Najmanje dva DAA namijenjena liječenju u skladu s patentnim zahtjevom 1, naznačena time što je navedeni pacijent zaražen HCV genotipom 4.
7. Najmanje dva DAA namijenjena liječenju u skladu s patentnim zahtjevom 1, naznačena time što je navedeni pacijent zaražen HCV genotipom 5.
8. Najmanje dva DAA namijenjena liječenju u skladu s patentnim zahtjevom 1, naznačena time što je navedeni pacijent zaražen HCV genotipom 6.
9. Najmanje dva DAA namijenjena liječenju u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačena time što je navedeni pacijent zaražen bez ciroze.
10. Najmanje dva DAA namijenjena liječenju u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačena time što navedeni pacijent ima kompenziranu cirozu.
11. Najmanje dva DAA namijenjena liječenju u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačena time što je navedeni pacijent pacijent bez prethodnog liječenja.
12. Najmanje dva DAA namijenjena liječenju u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačena time što je navedeni pacijent prethodno liječeni pacijent.
13. Najmanje dva DAA namijenjena liječenju u skladu s bilo kojim od patentnih zahtjeva 1-12, naznačena time što se navedena najmanje dva DAA sastoje od (1) Spoja 1, ili njegove farmaceutski prihvatljive soli, i (2) Spoja 2, ili njegove farmaceutski prihvatljive soli.
14. Najmanje dva DAA namijenjena liječenju u skladu s patentnim zahtjevom 13, naznačena time što se navedena najmanje dva DAA sastoje od (1) Spoja 1 i (2) Spoja 2.
15. Najmanje dva DAA namijenjena liječenju u skladu s bilo kojim od patentnih zahtjeva 1-14, naznačena time što se Spoj, ili njegovu farmaceutski prihvatljivu sol, i Spoj 2, ili njegovu farmaceutski prihvatljivu sol, primjenjuje jednom dnevno na navedenom pacijentu.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361783376P | 2013-03-14 | 2013-03-14 | |
| EP17165207.6A EP3213750B1 (en) | 2013-03-14 | 2014-03-14 | Combination of two antivirals for treating hepatitis c |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201575T1 true HRP20201575T1 (hr) | 2020-12-11 |
Family
ID=50588882
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171036TT HRP20171036T1 (hr) | 2013-03-14 | 2017-07-06 | Kombinacija dvaju antiviralnih sredstava za liječenje hepatitisa c |
| HRP20201575TT HRP20201575T1 (hr) | 2013-03-14 | 2020-10-05 | Kombinacija dva protuvirusna sredstva namijenjena liječenju hepatitisa c |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171036TT HRP20171036T1 (hr) | 2013-03-14 | 2017-07-06 | Kombinacija dvaju antiviralnih sredstava za liječenje hepatitisa c |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20140275099A1 (hr) |
| EP (3) | EP2968301B1 (hr) |
| JP (4) | JP6441303B2 (hr) |
| KR (2) | KR102210935B1 (hr) |
| CN (2) | CN108159393A (hr) |
| AU (2) | AU2014239563B2 (hr) |
| BR (1) | BR112015023017B1 (hr) |
| CA (1) | CA2901810C (hr) |
| CY (2) | CY1119025T1 (hr) |
| DK (2) | DK2968301T3 (hr) |
| EA (2) | EA033257B1 (hr) |
| ES (2) | ES2824473T3 (hr) |
| HK (2) | HK1244668A1 (hr) |
| HR (2) | HRP20171036T1 (hr) |
| HU (2) | HUE033010T2 (hr) |
| IL (1) | IL240419B (hr) |
| LT (2) | LT3213750T (hr) |
| MX (2) | MX362616B (hr) |
| NZ (2) | NZ719137A (hr) |
| PL (2) | PL2968301T3 (hr) |
| PT (2) | PT2968301T (hr) |
| RS (2) | RS56202B1 (hr) |
| SG (2) | SG10201708306WA (hr) |
| SI (2) | SI3213750T1 (hr) |
| TW (2) | TWI642436B (hr) |
| WO (1) | WO2014152514A1 (hr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2968301T3 (pl) | 2013-03-14 | 2017-09-29 | Abbvie Inc. | Kombinacja dwóch środków przeciwwirusowych do leczenia zapalenia wątroby typu C |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| US20150011481A1 (en) * | 2013-07-02 | 2015-01-08 | Abbvie Inc. | Methods for Treating HCV |
| CA2925328A1 (en) * | 2013-10-25 | 2015-04-30 | Abbvie, Inc. | Methods for treating hcv |
| US20150174194A1 (en) * | 2013-12-19 | 2015-06-25 | Abbvie Inc. | Methods for treating liver transplant recipients |
| EP3125890A1 (en) * | 2014-04-02 | 2017-02-08 | AbbVie Inc. | Methods for treating hcv |
| EP3125889A1 (en) * | 2014-04-02 | 2017-02-08 | AbbVie Inc. | Methods for treating hcv |
| EA201890160A1 (ru) * | 2015-06-26 | 2018-06-29 | Эббви Инк. | Твердые фармацевтические композиции для лечения вируса гепатита с |
| US20160375017A1 (en) | 2015-06-26 | 2016-12-29 | Abbvie Inc. | Solid Pharmaceutical Compositions for Treating HCV |
| MX2018000240A (es) * | 2015-07-08 | 2018-03-14 | Abbvie Inc | Metodos para tratar el vhc. |
| EP3324941A1 (en) * | 2015-07-17 | 2018-05-30 | AbbVie Inc. | Solid pharmaceutical compositions for treating hcv |
| JP7129703B2 (ja) | 2016-04-28 | 2022-09-02 | エモリー ユニバーシティー | アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用 |
| AU2017332771A1 (en) * | 2016-09-23 | 2019-04-04 | Abbvie Inc. | Dose adjustment |
| JP2018131439A (ja) * | 2017-02-14 | 2018-08-23 | アッヴィ・インコーポレイテッド | Ｈｃｖを処置する方法 |
| CA2981993A1 (en) * | 2017-08-02 | 2019-02-02 | Abbvie Inc. | Methods for treating hcv |
| US10606828B2 (en) * | 2017-10-19 | 2020-03-31 | Jpmorgan Chase Bank, N.A. | Storage correlation engine |
| CN112351799A (zh) * | 2018-04-10 | 2021-02-09 | 阿堤亚制药公司 | 具有硬化的hcv感染患者的治疗 |
| CA3120686A1 (en) | 2018-11-20 | 2020-05-28 | Abbvie Inc. | Methods for treating acute hcv |
| KR102077833B1 (ko) | 2018-12-10 | 2020-02-14 | 류형준 | 기능성 식품조성물 |
| CN111688355B (zh) | 2019-03-15 | 2022-04-12 | 精工爱普生株式会社 | 液体吸收体、液体吸收器以及液体喷出装置 |
| WO2020210100A1 (en) * | 2019-04-08 | 2020-10-15 | Abbvie Inc. | Solid pharmaceutical compositions for treating hcv |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| US8937150B2 (en) * | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| EA029145B1 (ru) * | 2010-09-21 | 2018-02-28 | Энанта Фармасьютикалз, Инк. | Ингибиторы hcv сериновой протеазы, полученные из макроциклического пролина |
| US8330139B2 (en) | 2011-03-25 | 2012-12-11 | Micron Technology, Inc. | Multi-level memory cell |
| WO2013059638A1 (en) | 2011-10-21 | 2013-04-25 | Abbvie Inc. | Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv |
| CN103826627B (zh) | 2011-10-21 | 2016-02-24 | 艾伯维公司 | 包含至少两种直接抗病毒剂和利巴韦林的组合物在制备治疗hcv的药物中的用途 |
| DK2897611T3 (da) * | 2012-09-18 | 2019-11-04 | Abbvie Inc | Fremgangsmåder til behandling af hepatitis c |
| PL2968301T3 (pl) | 2013-03-14 | 2017-09-29 | Abbvie Inc. | Kombinacja dwóch środków przeciwwirusowych do leczenia zapalenia wątroby typu C |
-
2014
- 2014-03-14 PL PL14719977T patent/PL2968301T3/pl unknown
- 2014-03-14 JP JP2016502431A patent/JP6441303B2/ja active Active
- 2014-03-14 SI SI201431674T patent/SI3213750T1/sl unknown
- 2014-03-14 EP EP14719977.2A patent/EP2968301B1/en not_active Revoked
- 2014-03-14 AU AU2014239563A patent/AU2014239563B2/en active Active
- 2014-03-14 EP EP17165207.6A patent/EP3213750B1/en active Active
- 2014-03-14 NZ NZ719137A patent/NZ719137A/en unknown
- 2014-03-14 EA EA201591702A patent/EA033257B1/ru unknown
- 2014-03-14 RS RS20170672A patent/RS56202B1/sr unknown
- 2014-03-14 HU HUE14719977A patent/HUE033010T2/en unknown
- 2014-03-14 TW TW103109530A patent/TWI642436B/zh not_active IP Right Cessation
- 2014-03-14 ES ES17165207T patent/ES2824473T3/es active Active
- 2014-03-14 WO PCT/US2014/027423 patent/WO2014152514A1/en active Application Filing
- 2014-03-14 LT LTEP17165207.6T patent/LT3213750T/lt unknown
- 2014-03-14 MX MX2015012538A patent/MX362616B/es active IP Right Grant
- 2014-03-14 HU HUE17165207A patent/HUE052113T2/hu unknown
- 2014-03-14 PL PL17165207T patent/PL3213750T3/pl unknown
- 2014-03-14 TW TW107108651A patent/TWI686196B/zh not_active IP Right Cessation
- 2014-03-14 DK DK14719977.2T patent/DK2968301T3/en active
- 2014-03-14 CA CA2901810A patent/CA2901810C/en active Active
- 2014-03-14 US US14/210,870 patent/US20140275099A1/en not_active Abandoned
- 2014-03-14 KR KR1020157029549A patent/KR102210935B1/ko active IP Right Grant
- 2014-03-14 KR KR1020217002760A patent/KR20210013344A/ko active Application Filing
- 2014-03-14 SG SG10201708306WA patent/SG10201708306WA/en unknown
- 2014-03-14 PT PT147199772T patent/PT2968301T/pt unknown
- 2014-03-14 BR BR112015023017-2A patent/BR112015023017B1/pt active IP Right Grant
- 2014-03-14 CN CN201810067970.1A patent/CN108159393A/zh active Pending
- 2014-03-14 EP EP20183791.1A patent/EP3766495A1/en active Pending
- 2014-03-14 NZ NZ631155A patent/NZ631155A/en unknown
- 2014-03-14 EA EA201991174A patent/EA201991174A1/ru unknown
- 2014-03-14 DK DK17165207.6T patent/DK3213750T3/da active
- 2014-03-14 ES ES14719977.2T patent/ES2624980T3/es active Active
- 2014-03-14 LT LTEP14719977.2T patent/LT2968301T/lt unknown
- 2014-03-14 RS RS20201198A patent/RS60881B1/sr unknown
- 2014-03-14 CN CN201480015311.3A patent/CN105073113B/zh not_active Expired - Fee Related
- 2014-03-14 PT PT171652076T patent/PT3213750T/pt unknown
- 2014-03-14 SG SG11201507364SA patent/SG11201507364SA/en unknown
- 2014-03-14 SI SI201430265A patent/SI2968301T1/sl unknown
-
2015
- 2015-08-06 IL IL240419A patent/IL240419B/en active IP Right Grant
- 2015-09-11 MX MX2020005054A patent/MX2020005054A/es unknown
-
2016
- 2016-05-03 AU AU2016202823A patent/AU2016202823B2/en active Active
- 2016-07-20 HK HK18103210.8A patent/HK1244668A1/zh unknown
- 2016-07-20 HK HK16108631.0A patent/HK1223817A1/zh unknown
-
2017
- 2017-06-21 CY CY20171100653T patent/CY1119025T1/el unknown
- 2017-07-06 HR HRP20171036TT patent/HRP20171036T1/hr unknown
-
2018
- 2018-11-22 JP JP2018219054A patent/JP6621902B2/ja active Active
-
2019
- 2019-11-19 JP JP2019208502A patent/JP2020037589A/ja active Pending
-
2020
- 2020-10-05 CY CY20201100930T patent/CY1123387T1/el unknown
- 2020-10-05 HR HRP20201575TT patent/HRP20201575T1/hr unknown
-
2021
- 2021-06-07 JP JP2021094935A patent/JP2021130720A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201575T1 (hr) | Kombinacija dva protuvirusna sredstva namijenjena liječenju hepatitisa c | |
| HRP20171898T1 (hr) | Kombinacija direktno djelujućih antivirusnih sredstava i ribavirina za liječenje hcv bolesnika | |
| HRP20180237T4 (hr) | Metode za liječenje hcv-a | |
| HRP20211224T1 (hr) | Derivati pirimidina za liječenje virusnih infekcija | |
| JP2014530874A5 (hr) | ||
| HRP20191957T1 (hr) | Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba | |
| JP2016513703A5 (hr) | ||
| RU2019114665A (ru) | Противовирусные композиции для лечения инфекций, связанных с коронавирусами | |
| JP2013507439A5 (hr) | ||
| HRP20171512T1 (hr) | Derivati betulina | |
| HRP20230274T1 (hr) | Kemijski spojevi | |
| EA201490836A1 (ru) | Комбинационное лечение (например, с abt-072 или abt-333) с помощью daa для применения при лечении hcv | |
| HRP20150725T1 (hr) | Kondenzirani imidazolilimidazoli kao antivirusni spojevi | |
| MX2016012799A (es) | Metodos para tratar el virus de la hepatitis c. | |
| JP2016508134A5 (hr) | ||
| EP2583677A3 (en) | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon. | |
| SA517382236B1 (ar) | نيوكليدات بيورين مستبدلة بـ 2- n6 معدل مستبدل بــــ بيتا-d-2´-ديوكسي-2´-ألفا-فلورو-2 ´-بيتا-c لمعالجة hcv | |
| RU2015114543A (ru) | Способы лечения гепатита с | |
| JP2015193630A5 (hr) | ||
| WO2015084741A3 (en) | Methods of treating hepatitis c virus infection in subjects with cirrhosis | |
| MX2018000240A (es) | Metodos para tratar el vhc. | |
| RU2013148779A (ru) | Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени | |
| MX2014009850A (es) | Spiro [2.4] heptanos para aplicaciones relacionadas con el tratamiento de infecciones de flaviviridae. | |
| MX2016012722A (es) | Metodos para tratar el virus de la hepatitis c. | |
| RU2015114566A (ru) | Способы лечения гепатита с |